2B) (genotype treatment:F(1,17)= 13.480,p< 0.01 for PV, andF(1,17)= 55.472,p< 0.001 for oxDHE). as phencyclidine (PCP) and ketamine reproduce both negative and positive symptoms of schizophrenia, and offers therefore been used to model its pathophysiological features (Javitt, 2007). The acute propsychotic effects of these antagonists are believed to Mouse monoclonal to TNK1 arise from specific effects on inhibitory circuits that lead to disinhibition of excitatory systems (Olney et al., 1999;Tomitaka et al., 2000;Holcomb et al., 2005;Homayoun and Moghaddam, 2007). Although acute exposures to NMDA-R antagonists produce increased rate of metabolism in frontal areas, these effects are transient. Subchronic exposures, however, produce more persistent neurochemical changes that include major depression in mind metabolic activity in the prefrontal cortex (PFC), as well as within constructions of the auditory system and the reticular nucleus of the thalamus, and resemble more closely the alterations observed in schizophrenia individuals (Jentsch and Roth, 1999;Cochran et al., 2003). These subchronic exposures lead to reduced expression of the calcium-binding protein parvalbumin (PV) in GABAergic interneurons in rodents and nonhuman primates (Cochran et al., 2003;Keilhoff et al., 2004;Rujescu et al., 2006;Morrow et al., 2007), a deficiency that has been consistently observed in postmortem mind samples of schizophrenic individuals. Initial studies showing decreased manifestation of GAD67, the main isoform synthesizing GABA (Akbarian et al., 1995), were subsequently supported by studies showing that the manifestation of PV inside a subset of fast-spiking inhibitory interneurons was also reduced in postmortem samples of schizophrenic individuals (Beasley and Reynolds, 1997;Hashimoto et al., 2003). This loss of GABAergic phenotype in PV-interneurons led to the suggestion that dysfunction of these fast-spiking inhibitory interneurons may be a core feature of the disease (Lewis et al., 2005). We have recently confirmed that prolonged exposure to ketamine and additional NMDA-R antagonists decreases GAD67 and parvalbumin in the same neuronsin vitro(Kinney et al., 2006), and that exposure to subanesthetic doses on 2 consecutive days is sufficient to induce the loss of phenotype of these interneurons in mouse PFC (Behrens et al., 2007). Accumulating evidence suggests that schizophrenia individuals suffer from diminished antioxidant defenses, and a recent clinical trial showed that increasing these defenses may ameliorate symptoms of the disease (Berk et al., 2008). We have recently demonstrated that the initial disinhibition caused by exposure to ketamine at subanesthetic doses induced the activation of the superoxide-producing enzyme NADPH oxidase (Nox)in vitroandin vivo, and that the superoxide produced is responsible for the loss of phenotype of PV-interneurons (Behrens et al., 2007). Furthermore, we showed that preventing the activation of Nox ameliorates the effects of ketamine on these interneurons. However, the mechanism(s) by which ketamine induces the activation of Nox were unknown. Here we present data showing that neuronal production of interleukin-6 (IL-6) is necessary and adequate to induce and activate Nox on ketamine N-Desmethylclozapine exposurein vitroandin vivo. == Materials and Methods == == == == == == Materials. == Antibodies used were as follows: anti-parvalbumin, anti-calbindin, and anti-calretinin rabbit polyclonals from Swant, anti-GAD67 monoclonal from Millipore Bioscience Study Reagents, anti-Nox2 from Santa Cruz Biotechnology; anti-IL-6-obstructing antibodies were goat anti-recombinant mouse IL-6 total IgG portion, and rat anti-recombinant mouse IL-6 (IgG1) from R&D Systems. Unless otherwise stated, all reagents were from Sigma and cells culture press from Invitrogen. The spin traps 5-(diisopropoxyphosphoryl)-5-methyl-1-pyrroline-N-oxide (DIPPMPO) and 5-(diethylphosphoryl)-5-methyl-1-pyrroline-N-oxide (DEPMPO) were from Alexis Biochemicals. == Maintenance of mice and administration of ketamine and dihydroethidium. == Male C57BL/6,gp91phox/, N-Desmethylclozapine andIL-6/mice were from The Jackson N-Desmethylclozapine Laboratory at 8 weeks of age and housed in our facility until 1215 weeks, when they were utilized for experiments. Ketamine (30 mg/kg) was applied intraperitoneally singly or.